New FMD vaccine signals advance in global disease control

Published on: Mar 28, 2013

Researchers in the U.K. have developed a new methodology to produce a vaccine for foot and mouth disease virus (FMDv), according to an announcement from the U.K.'s Biotechnology & Biological Sciences Research Council (BBSRC).

Because the vaccine is all synthetic, made up of tiny protein shells designed to trigger optimum immune response, it doesn't rely on growing live infectious virus and is, therefore, safer to produce, the announcement said.

Furthermore, these empty shells have been engineered to be more stable; making the vaccine much easier to store and reducing the need for a cold chain. BBSRC said this is important because it represents "a big step forward in the global campaign" to control FMDv in countries where the disease is endemic, and could significantly reduce the threat to countries currently free of the disease.

Also, this new approach to making and stabilizing vaccine could also affect on how viruses from the same family -- including polio -- are fought, BBSRC said.

This collaborative research was led by Professor David Stuart at Diamond Light Source and the University of Oxford and Dr. Bryan Charleston at The Pirbright Institute.

Charleston, whose team at The Pirbright Institute has developed a detailed understanding of the immune response to FMDv in cattle and is leading the vaccination trials work, said, "The FMDv epidemic in the U.K. in 2001 was disastrous and cost the economy billions of pounds in control measures and compensation. As a result of the outbreak, the Royal Society recommended new approaches should be developed to control the virus should it happen again.

"Using our knowledge of the immune responses to FMDv in cattle, we were able to define the characteristics that needed to be incorporated into the new vaccine platform to induce protection," he added.

Stuart explained, "What we have achieved here is close to the holy grail of (FMDv) vaccines. Unlike the traditional vaccines, there is no chance that the empty shell vaccine could revert to an infectious form. This work will have a broad and enduring impact on vaccine development, and the technology should be transferable to other viruses from the same family, such as poliovirus and hand, foot and mouth disease, a human virus which is currently endemic in Southeast Asia,"

Key results were published March 27 in the journal PLOS Pathogens. The work is principally funded by the U.K. Department for Environment, Food & Rural Affairs and the Wellcome Trust.

Clinical trials of the synthetic shell-based vaccine on cattle have shown that it is as effective as current vaccines, BBSRC said. While a commercial product is still several years away, the team hopes that the technology can be transferred as quickly as possible to make it available to a global market.